Fulminant demyelinating disease is a heading that covers acute disseminated encephalomyelitis and its variant acute hemorrhagic leukoencephalitis (Hurst disease), severe relapses of multiple sclerosis (MS), variants of MS (tumefactive MS, Marburg variant, Balo concentric sclerosis, myelinoclastic diffuse sclerosis), and neuromyelitis optica-spectrum disorders associated with aquaporin autoimmunity. These categories of inflammatory demyelinating disease often prompt hospital admission and many necessitate intensive care monitoring due to the aggressive nature of the illness and associated neurologic morbidity. In this review, we highlight the discriminating clinical, radiographic, and pathologic features of these disorders. Acute management is often accomplished with use of high-dose intravenous steroids and plasma exchange. Aggressive disease may respond to immunosuppression. Prognosis for recovery varies among the disorders but most patients improve. Factors influencing outcome are also discussed.
MengeTHemmerBNesslerSAcute disseminated encephalomyelitis: an update. Arch Neurol. 2005;62(11):1673–1680.
2.
MarchioniERavagliaSPiccoloGPostinfectious inflammatory disorders: subgroups based on prospective follow-up. Neurology. 2005;65(7):1057–1065.
3.
HynsonJLKornbergAJColemanLTClinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology. 2001;56(10):1308–1312.
4.
DaleRCde SousaCChongWKCoxTCHardingBNevilleBG. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain. 2000;123(Pt 12):2407–2422.
5.
LeakeJAAlbaniSKaoAS, Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical, and laboratory features. Pediatr Infect Dis J. 2004;23(8):756–764.
6.
AlperGHeymanRWangL. Multiple sclerosis and acute disseminated encephalomyelitis diagnosed in children after long-term follow-up: comparison of presenting features. Dev Med Child Neurol. 2009;51(6):480–486.
TenembaumSChamolesNFejermanN. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002;59(8):1224–1231.
9.
De SezeJDebouverieMZephirHAcute fulminant demyelinating disease: a descriptive study of 60 patients. Arch Neurol. 2007;64(10):1426–1432.
10.
SchwarzSMohrAKnauthMWildemannBStorch-HagenlocherB. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001;56(10):1313–1318.
11.
KruppLBBanwellBTenembaumS. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68(16 suppl 2):S7–S12.
12.
YoungNPWeinshenkerBGParisiJEPerivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis. Brain. 2010;133(Pt 2):333–348.
13.
HonkaniemiJDastibarPKaharaVHaapasaloH. Delayed MR imaging changes in acute disseminated encephalomyelitis. Am J Neuroradiol. 2001;22(6):1117–1124.
14.
RossiA.Imaging of acute disseminated encephalomyelitis. Neuroimag Clin N Am. 2008;18(1):149–161.
15.
SonevilleRDemeretSKleinIAcute disseminated encephalomyelitis in the intensive care unit: clinical features and outcome of 20 adults. Intensive Care Med. 2008;34(3):528–532.
16.
BalasubramanyaKSKovoorJMJayakumarPNDiffusion-weighted imaging and proton MR spectroscopy in the characterization of acute disseminated encephalomyelitis. Neuroradiology. 2007;49(2):177–183.
17.
CallenDJShroffMMBransonHMRole of MRI in the differentiation of ADEM from MS in children. Neurology. 2009;72(11):968–973.
18.
VerheyLHBransonHMShroffMMMRI parameters for prediction of multiple sclerosis diagnosis in children with acute CNS demyelination: a prospective national cohort study. Lancet Neurol. 2011;10(12):1065–1073.
19.
PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.
20.
KetelslegersIAVisserIERNeuteboomRFBoonMCatsman-BerrevoetsCEHintzenRQ. Disease course and outcome of acute disseminated encephalomyelitis is more severe in adults than in children. Mult Scler. 2010;17(4):441–448.
21.
HuWLucchinettiCF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol. 2009;31(4):439–453.
22.
Von Stuckrad-BarreSKlippelEFoerchCLangJMdu Mesnil de RochemontRSitzerM.Hemicraniectomy as a successful treatment of mass effect in aute disseminated encephalomyelitis. Neurology. 2003;61(3):420–421.
23.
RefaiDLeeMCGoldenbergFDFrankJI. Decompressive hemicraniectomy for acute disseminated encephalomyelitis. case report. Neurosurgery. 2005;56(4):E872.
24.
TakataTHirakawaMSakuraiMKanazawaI. Fulminant form of acute disseminated encephalomyelitis: successful treatment with hypothermia. J Neurol Sci. 1999;165(1):94–97.
25.
RyanLJBowmanRZantekNDUse of therapeutic plasma exchange in the management of acute hemorrhagic leukoencephalitis: a case report and review of the literature. Hemapheresis. 2007;47(6):981–986.
26.
MayrWTPittockSJMcClellandRLJorgensenNWNoseworthyJHRodriguezM.Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology. 2003;61(10):1373–1377.
27.
WattamwarPRBahetiNNKesavadasCNairMRadhakrishnanA. Evolution and long-term outcome in patients presenting with large demyelinating lesions as their first clinical event. J Neurol Sci. 2010;297(1-2):29–35.
28.
LucchinettiCFGavrilovaRHMetzIClinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain. 2008;131(Pt 7):1759–1775.
29.
MasdeuJCMoreiraJTrasiSThe open ring. A new imaging sign in demyelinating disease. J Neuroimaging. 1996;6(2)104–107.
KrivickasLSHochbergFHFreemanS. Chronic inflammatory demyelinating polyradiculoneuropathy with tumefactive central demyelination. Muscle Nerve. 2006;33(2):283–288.
32.
KiriyamaTKataokaHTaokaTCharacteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30mm. J Neuroimaging. 2011;21(2):e69–e77.
33.
MasdeuJCQuintoCOliveraCTennerMLeslieDVisintainerP. Open-ring imaging sign: highly specific for atypical brain demyelination. Neurology. 2000;54(17):1427–1433.
34.
BotJCBarkhofFPolmanCHSpinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology. 2004;62(2):226–233.
35.
SeewannAEnzingerCFilippiMMRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain: a review of reported findings. J Neurol. 2008;255(1):1–10
36.
MillerRCLachanceDHLucchinettiCFMultiple sclerosis, brain radiotherapy, and risk of neurotoxicity: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys. 2006;66(4):1178–1186.
KepesJJ. Large focal tumor-like demyelinating lesions of the brain: intermediate entity between multiple sclerosis and acute disseminated encephalomyelitis? A study of 31 patients. Ann Neurol. 1993;33(1):18–27.
40.
WingerchukDMLennonVALucchinettiCFPittockSJWeinshenkerBG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–815.
41.
KimWKimSHLeeSHBrain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler. 2011;17(9):1107–1112.
42.
LennonVAWingerchukDMKryzerTJA serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112.
43.
SellnerJBoggildMClanetMEFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019–1032.
44.
Cabrera-GomezJKisterI.Conventional brain MRI in neuromyelitis optica. Eur J Neurol. 2011;19(6):812–819
45.
PopescuBFLennonVAParisiJENeuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology. 2011;76(14):1229–1237.
LucchinettiCFMandlerRNMcGavernDA role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain. 2002;127(Pt 7):1450–1461.
50.
RoemerSFParisiJELennonVAPattern specific loss of aquaporin 4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130(Pt 5):1194–1205.
51.
WingerchukDMWeinshenkerBG. Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology. 2003;60(5):848–853.
52.
MatsushitaTIsobeNPiaoHReappraisal of brain MRI features in patients with multiple sclerosis and neuromyelitis optica according to anti-aquaporin-4 antibody status. J Neurol Sci. 2010;291(1-2):37–43.
53.
WeinshenkerBGO’BrienPCPettersonTMA randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol. 1999;46(6):878–886.
54.
CorteseIChaudhryVSoYTCantorFCornblathDRRae-GrantA.Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2011;76(3):294–300.
55.
MaganaSMKeeganMWeinshenkerBG, Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol. 2011;68(7):870–878.
56.
KeeganMKonigFMcClellandRRelationship between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005;366(9485):579–582.
57.
SahlasDJMillerSPGuerinMVeilleuxMFrancisG. Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin. Neurology. 2000;54(6):1370–1372.
58.
MarchioniEMarinou-AktipiKUggettiCEffectiveness of intravenous immunoglobulin treatment in adult patients with steroid-resistant monophasic or recurrent acute disseminated encephalomyelitis. J Neurol. 2002;249(1):100–104.
TurattiMGajofattoARossiFVedovelloMBenedettiMD. Long survival and clinical stability in Marburg’s variant multiple sclerosis. Neurol Sci. 2010;31(6):807–811.
61.
NozakiKAbou-FayassalN.High dose cyclophosphamide treatment in Marburg variant multiple sclerosis: A case report. J Neurol Sci. 2010;296(1-2):121–123.
62.
JefferyDRLefkowitzDSCrittendenJP. Treatment of Marburg variant multiple sclerosis with mitoxantrone. J Neuroimaging. 2004;14(1):58–62.
CostanziCMatielloMLucchinettiCFAzathioprine: tolerability, efficancy, and predictors of benefit in neuromyelitis optica. Neurology. 2011;77(7):659–666.
65.
JacobAMatielloMWeinshenkerBTreatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66(9):1128–1133.
66.
JacobAWeinshenkerBViolichITreatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008;65(11):1443–1448.
67.
RagelBTFassettDRBaringerJRBrowdSRDaileyAT. Decompressive hemicraniectomy for tumefactive demyelination with transtentorial herniation: observation. Surg Neurol. 2006;65(6):582–583.
68.
CensoriBAgostinisCPartziguianTGazzanigaGBiroliFMamoliA. Large demyelinating brain lesion mimicking a herniating tumour. Neurol Sci. 2001;22(4):325–329.
69.
Gonzalez SanchezJJEnsenyatNJde NotarisMArboixJRGarcíaCGRodríguezEF. A case of malignant monophasic multiple sclerosis (Marburg’s disease type) successfully treated with decompressive hemicraniectomy. J Neurol Neurosurg Psychiatry. 2010;81(9):1056–1057.
